{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:28:52Z","timestamp":1787761732471,"version":"build-2784847793"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>A number of research articles has been published evaluating safety and efficacy of drugs against COVID-19. This study was undertaken to collate and review the information regarding common proposed anti- viral drugs for easy reference.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The literature was search was done using terms like severe acute respiratory syndrome or SARS-CoV-2 or 2019-nCoV or SARS-CoV or COVID-19 in combination with drugs or treatment or pharmaco-therapy using PubMed and google scholar to identify relevant articles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Despite showing good early results, hydroxychloroquine and lopinavir-ritonavir has not shown clinical benefit in randomized controlled trials. However lopinavir in combination with other drugs specially interferon is being investigated. Remdesivir has shown positive effect in terms of clinical improvement and continued to being investigated alone or in combination with other drugs. Favipiravir has shown mixed results and more data from adequately powered study is needed to prove its efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Many drugs which showed positive effect in initial studies could not replicate the same benefit in large randomized controlled trials. There is need to evaluate efficacy and safety of drugs based on high quality evidence before allowing it to be used in general population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jpbs.jpbs_498_20","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T05:13:37Z","timestamp":1675746817000},"page":"163-171","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["A Narrative Review of Antiviral Drugs Used for COVID-19 Pharmacotherapy"],"prefix":"10.4103","volume":"13","author":[{"given":"Subodh","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj K.","family":"Saurabh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Maharshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dibyajyoti","family":"Saikia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R3-3-20240829","doi-asserted-by":"crossref","first-page":"10970","DOI":"10.1073\/pnas.2005615117","article-title":"Effective treatment of severe covid-19 patients with tocilizumab","volume":"117","author":"Xu","year":"2020","journal-title":"Proc Natl Acad Sci u s a"},{"key":"R4-3-20240829","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/jmv.25801","article-title":"Tocilizumab treatment in covid-19: a single center experience","volume":"92","author":"Luo","year":"2020","journal-title":"j Med Virol"},{"key":"R5-3-20240829","doi-asserted-by":"crossref","first-page":"102568","DOI":"10.1016\/j.autrev.2020.102568","article-title":"Tocilizumab for the treatment of severe covid-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in brescia, Italy","volume":"19","author":"Toniati","year":"2020","journal-title":"Autoimmun Rev"},{"key":"R6-3-20240829","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-ncov) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"key":"R7-3-20240829","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of sars: initial virological and clinical findings","volume":"59","author":"Chu","year":"2004","journal-title":"Thorax"},{"key":"R8-3-20240829","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jcv.2004.03.003","article-title":"In vitro susceptibility of 10 clinical isolates of sars coronavirus to selected antiviral compounds","volume":"31","author":"Chen","year":"2004","journal-title":"j Clin Virol"},{"key":"R9-3-20240829","first-page":"1824","article-title":"Pharmacologic treatments for coronavirus disease 2019 (COVID 19): A review","volume":"323","author":"Sanders","year":"2020","journal-title":"JAMA"},{"key":"R10-3-20240829","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule gs-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"key":"R11-3-20240829","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.antiviral.2009.02.198","article-title":"t-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of rna viral infections","volume":"82","author":"Furuta","year":"2009","journal-title":"Antiviral Res"},{"key":"R13-3-20240829","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41467-019-13940-6","article-title":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against mers-cov","volume":"11","author":"Sheahan","year":"2020","journal-title":"Nat Commun"},{"key":"R14-3-20240829","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1073\/pnas.1922083117","article-title":"Prophylactic and therapeutic remdesivir (gs-5734) treatment in the rhesus macaque model of mers-cov infection","volume":"117","author":"de Wit","year":"2020","journal-title":"Proc Natl Acad Sci usa"},{"key":"R16-3-20240829","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the Treatment of Covid-19 - Final Report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"R17-3-20240829","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe covid-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"R18-3-20240829","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa2015301","article-title":"Remdesivir for 5 or 10 days in patients with severe Covid-19","volume":"383","author":"Goldman","year":"2020","journal-title":"N Engl J Med"},{"key":"R19-3-20240829","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe covid-19","volume":"382","author":"Grein","year":"2020","journal-title":"n Engl j Med"},{"key":"R20-3-20240829","doi-asserted-by":"crossref","first-page":"104899","DOI":"10.1016\/j.phrs.2020.104899","article-title":"Compassionate remdesivir treatment of severe covid-19 pneumonia in intensive care unit (ICU) and non-icu patients: clinical outcome and differences in post-treatment hospitalisation status","volume":"158","author":"Antinori","year":"2020","journal-title":"Pharmacol Res"},{"key":"R21-3-20240829","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1016\/j.ajem.2020.07.030","article-title":"Acute chloroquine and hydroxychloroquine toxicity: A review for emergency clinicians","volume":"38","author":"Della Porta","year":"2020","journal-title":"Am J Emerg Med"},{"key":"R22-3-20240829","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1001\/archophthalmol.2010.321","article-title":"Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy","volume":"129","author":"Michaelides","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"R23-3-20240829","doi-asserted-by":"crossref","first-page":"434","DOI":"10.3109\/08923973.2013.780078","article-title":"Chloroquine cardiomyopathy: a review of the literature","volume":"35","author":"T\u00f6nnesmann","year":"2013","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"R25-3-20240829","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1056\/NEJMoa2019014","article-title":"Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19","volume":"383","author":"Cavalcanti","year":"2020","journal-title":"N Engl J Med"},{"key":"R29-3-20240829","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of covid-19: results of an open-label non-randomized clinical trial","volume":"56","author":"Gautret","year":"2020","journal-title":"Int j Antimicrob Agents"},{"key":"R30-3-20240829","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMoa2012410","article-title":"Observational study of hydroxychloroquine in hospitalized patients with covid-19","volume":"382","author":"Geleris","year":"2020","journal-title":"n Engl j Med"},{"key":"R31-3-20240829","doi-asserted-by":"crossref","first-page":"101663","DOI":"10.1016\/j.tmaid.2020.101663","article-title":"Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 covid-19 patients with at least a six-day follow up: a pilot observational study","volume":"34","author":"Gautret","year":"2020","journal-title":"Travel Med Infect Dis"},{"key":"R32-3-20240829","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.medj.2020.06.001","article-title":"Outcomes of hydroxychloroquine usage in United States Veterans Hospitalized with COVID-19","volume":"1","author":"Magagnoli","year":"2020","journal-title":"Med (N Y"},{"key":"R33-3-20240829","doi-asserted-by":"crossref","first-page":"m1844","DOI":"10.1136\/bmj.m1844","article-title":"Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data","volume":"369","author":"Mah\u00e9vas","year":"2020","journal-title":"BMJ"},{"key":"R34-3-20240829","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1007\/s11427-020-1732-2","article-title":"Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19?","volume":"63","author":"Yu","year":"2020","journal-title":"Sci China Life Sci"},{"key":"R35-3-20240829","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (t-705), a broad spectrum inhibitor of viral rna polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc Jpn Acad Ser b Phys Biol Sci"},{"key":"R40-3-20240829","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.3346\/jkms.2020.35.e79","article-title":"Case of the index patient who caused tertiary transmission of covid-19 infection in Korea: the application of lopinavir\/ritonavir for the treatment of covid-19 infected pneumonia monitored by quantitative rt-pcr","volume":"35","author":"Lim","year":"2020","journal-title":"j Korean Med Sci"},{"key":"R41-3-20240829","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/jmv.25729","article-title":"a systematic review of lopinavir therapy for sars coronavirus and mers coronavirus-a possible reference for coronavirus disease-19 treatment option","volume":"92","author":"Yao","year":"2020","journal-title":"j Med Virol"},{"key":"R42-3-20240829","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"a trial of lopinavir-ritonavir in adults hospitalized with severe covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"n Engl j Med"},{"key":"R43-3-20240829","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","article-title":"Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with covid-19: an open-label, randomised, phase 2 trial","volume":"395","author":"Hung","year":"2020","journal-title":"Lancet"},{"key":"R44-3-20240829","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.medj.2020.04.001","article-title":"Efficacy and safety of lopinavir\/ritonavir or arbidol in adult patients with mild\/moderate COVID-19: An exploratory randomized controlled trial","volume":"1","author":"Li","year":"2020","journal-title":"Med (N Y"},{"key":"R45-3-20240829","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jinf.2020.03.060","article-title":"Arbidol monotherapy is superior to lopinavir\/ritonavir in treating covid-19","volume":"81","author":"Zhu","year":"2020","journal-title":"j Infect"},{"key":"R46-3-20240829","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jama.2020.16349","article-title":"Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: A randomized clinical trial?","volume":"324","author":"Spinner","year":"2020","journal-title":"JAMA"}],"container-title":["Journal of Pharmacy and Bioallied Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jpbs.JPBS_498_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:04:00Z","timestamp":1787760240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jpbs.JPBS_498_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/jpbs.jpbs_498_20","relation":{},"ISSN":["0976-4879"],"issn-type":[{"value":"0976-4879","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]}}}